cagrilintide vs MET-233i

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Obesity

Shared mechanism: Amylin receptor · full Obesity pipeline

cagrilintide

Developed by Novo Nordisk

Phase 3 in Obesitypeptide
Reliable signal

NCT03856047 · Phase 2 · completed

The trial randomized participants to five active doses, a pooled placebo, and an active liraglutide comparator arm, with quadruple-blinding (participant, care provider, investigator, and outcomes assessor all masked) and roughly 100 participants per arm. The primary endpoint, percent change in body weight at 26 weeks, is the regulator-accepted physiological measure for obesity trials, and every cagrilintide dose showed a statistically significant weight-loss advantage over placebo (p-values ranging from 0.0002 to <.0001), so the primary comparison was clearly met in the favorable direction.

Next expected readout: January 2027 · NCT07411560 (registry estimate)

Reported efficacy

Change in Body Weight (%) (From baseline (week 0) to week 26): Change in Body Weight (%) (From baseline (week 0) to week 26): Cagrilintide 0.3 mg -6.1% (Standard Deviation 3.9) | Cagrilintide 0.6 mg -6.9% (Standard Deviation 5.4) | Cagrilintide 1.2 mg -8.5% (Standard Deviation 5.4) | Cagrilintide 2.4 mg -9.5% (Standard Deviation 6.2) | Cagrilintide 4.5 mg -10.8% (Standard Deviation 5.5) vs Liraglutide 3.0 mg -8.5% (Standard Deviation 5.6) | Pooled Placebo -3% (Standard Deviation 5.2) (met)

Result source: NCT03856047

MET-233i

Developed by Pfizer and partners

Phase 1/2 in Obesitypeptide
Weak signal

NCT07022977 · Phase 1 · completed

A randomised, double-blind single- and multiple-ascending-dose Phase 1 study in 144 otherwise healthy adults with obesity or overweight. Its primary endpoint is the occurrence of treatment-emergent adverse events and weight change is only secondary, so it is not efficacy evidence; no results are posted.

Next expected readout: January 2027 · NCT07725809 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Obesity

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointcagrilintideMET-233i
Body weight, % change-10.8% vs -3%−7.8 vs placebo4.5 mg · wk 26 · n 97NCT03856047
4 other results
  • -9.5% vs -3% 2.4 mg · wk 26 · n 99 · Phase 2 · primary NCT03856047
  • -8.5% vs -3% 1.2 mg · wk 26 · n 98 · Phase 2 · primary NCT03856047
  • -6.9% vs -3% 0.6 mg · wk 26 · n 97 · Phase 2 · primary NCT03856047
  • -6.1% vs -3% 0.3 mg · wk 26 · n 96 · Phase 2 · primary NCT03856047
—Not reported
Weight loss of 5% or more88.7% vs 30.9%+57.8 vs placebo4.5 mg · wk 26 · n 80NCT03856047
4 other results
  • 74.1% vs 30.9% 2.4 mg · wk 26 · n 80 · Phase 2 · secondary NCT03856047
  • 75.8% vs 30.9% 1.2 mg · wk 26 · n 72 · Phase 2 · secondary NCT03856047
  • 62.0% vs 30.9% 0.6 mg · wk 26 · n 82 · Phase 2 · secondary NCT03856047
  • 57.5% vs 30.9% 0.3 mg · wk 26 · n 83 · Phase 2 · secondary NCT03856047
—Not reported
Weight loss of 10% or more53.5% vs 10.4%+43.1 vs placebo4.5 mg · wk 26 · n 80NCT03856047
4 other results
  • 44.0% vs 10.4% 2.4 mg · wk 26 · n 80 · Phase 2 · secondary NCT03856047
  • 35.8% vs 10.4% 1.2 mg · wk 26 · n 72 · Phase 2 · secondary NCT03856047
  • 24.1% vs 10.4% 0.6 mg · wk 26 · n 82 · Phase 2 · secondary NCT03856047
  • 15.3% vs 10.4% 0.3 mg · wk 26 · n 83 · Phase 2 · secondary NCT03856047
—Not reported
Waist circumference, change (cm)-9.5 vs -3.4−6.1 vs placebo4.5 mg · wk 26 · n 97NCT03856047
4 other results
  • -8.1 vs -3.4 2.4 mg · wk 26 · n 99 · Phase 2 · secondary NCT03856047
  • -7.7 vs -3.4 1.2 mg · wk 26 · n 98 · Phase 2 · secondary NCT03856047
  • -6.2 vs -3.4 0.6 mg · wk 26 · n 97 · Phase 2 · secondary NCT03856047
  • -6.2 vs -3.4 0.3 mg · wk 26 · n 96 · Phase 2 · secondary NCT03856047
—Not reported

Body weight, % change

cagrilintide
-10.8% vs -3%−7.8 vs placebo4.5 mg · wk 26 · n 97NCT03856047
4 other results
  • -9.5% vs -3% 2.4 mg · wk 26 · n 99 · Phase 2 · primary NCT03856047
  • -8.5% vs -3% 1.2 mg · wk 26 · n 98 · Phase 2 · primary NCT03856047
  • -6.9% vs -3% 0.6 mg · wk 26 · n 97 · Phase 2 · primary NCT03856047
  • -6.1% vs -3% 0.3 mg · wk 26 · n 96 · Phase 2 · primary NCT03856047
MET-233i
—Not reported

Weight loss of 5% or more

cagrilintide
88.7% vs 30.9%+57.8 vs placebo4.5 mg · wk 26 · n 80NCT03856047
4 other results
  • 74.1% vs 30.9% 2.4 mg · wk 26 · n 80 · Phase 2 · secondary NCT03856047
  • 75.8% vs 30.9% 1.2 mg · wk 26 · n 72 · Phase 2 · secondary NCT03856047
  • 62.0% vs 30.9% 0.6 mg · wk 26 · n 82 · Phase 2 · secondary NCT03856047
  • 57.5% vs 30.9% 0.3 mg · wk 26 · n 83 · Phase 2 · secondary NCT03856047
MET-233i
—Not reported

Weight loss of 10% or more

cagrilintide
53.5% vs 10.4%+43.1 vs placebo4.5 mg · wk 26 · n 80NCT03856047
4 other results
  • 44.0% vs 10.4% 2.4 mg · wk 26 · n 80 · Phase 2 · secondary NCT03856047
  • 35.8% vs 10.4% 1.2 mg · wk 26 · n 72 · Phase 2 · secondary NCT03856047
  • 24.1% vs 10.4% 0.6 mg · wk 26 · n 82 · Phase 2 · secondary NCT03856047
  • 15.3% vs 10.4% 0.3 mg · wk 26 · n 83 · Phase 2 · secondary NCT03856047
MET-233i
—Not reported

Waist circumference, change (cm)

cagrilintide
-9.5 vs -3.4−6.1 vs placebo4.5 mg · wk 26 · n 97NCT03856047
4 other results
  • -8.1 vs -3.4 2.4 mg · wk 26 · n 99 · Phase 2 · secondary NCT03856047
  • -7.7 vs -3.4 1.2 mg · wk 26 · n 98 · Phase 2 · secondary NCT03856047
  • -6.2 vs -3.4 0.6 mg · wk 26 · n 97 · Phase 2 · secondary NCT03856047
  • -6.2 vs -3.4 0.3 mg · wk 26 · n 96 · Phase 2 · secondary NCT03856047
MET-233i
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

MET-233i: no structured comparison results are available for Obesity.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. cagrilintide: 3 of 4 rows · MET-233i: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metriccagrilintide
Dropout rate
6.9%4.5 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
show 4 more results
1%2.4 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
3.9%1.2 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
3%0.6 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
4%0.3 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
Discontinued due to AEs
—4.5 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
show 4 more results
—2.4 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
—1.2 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
—0.6 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
—0.3 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
Serious AEs
4%4.5 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
show 4 more results
2.9%2.4 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
6.9%1.2 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
2%0.6 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
5.9%0.3 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
Most frequent reported AEs
4.5 mg
nausea 46.5% (placebo 17.8%)
constipation 20.8% (placebo 6.9%)
fatigue 19.8% (placebo 3%)
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
show 4 more results
2.4 mg
nausea 31.4% (placebo 17.8%)
diarrhoea 17.6% (placebo 8.9%)
constipation 16.7% (placebo 6.9%)
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
1.2 mg
nausea 36.3% (placebo 17.8%)
nasopharyngitis 12.7% (placebo 9.9%)
headache 10.8% (placebo 11.9%)
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
0.6 mg
nausea 27% (placebo 17.8%)
diarrhoea 10% (placebo 8.9%)
constipation 9% (placebo 6.9%)
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
0.3 mg
nausea 19.8% (placebo 17.8%)
diarrhoea 14.9% (placebo 8.9%)
constipation 10.9% (placebo 6.9%)
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

cagrilintide

Weight -10.8% (n=97) vs -3% (n=95) placebo @ 26wk4.5 mg
percent change · % of baseline
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
show 4 more results
-9.5% (n=99) vs -3% (n=95) placebo @ 26wk2.4 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
-8.5% (n=98) vs -3% (n=95) placebo @ 26wk1.2 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
-6.9% (n=97) vs -3% (n=95) placebo @ 26wk0.6 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
-6.1% (n=96) vs -3% (n=95) placebo @ 26wk0.3 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
Weight Loss 5% 88.74% (n=80) vs 30.9% (n=79) placebo @ 26wk4.5 mg
responder rate · % of participants
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
show 4 more results
74.12% (n=80) vs 30.9% (n=79) placebo @ 26wk2.4 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
75.84% (n=72) vs 30.9% (n=79) placebo @ 26wk1.2 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
61.98% (n=82) vs 30.9% (n=79) placebo @ 26wk0.6 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
57.47% (n=83) vs 30.9% (n=79) placebo @ 26wk0.3 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
Weight Loss 10% 53.49% (n=80) vs 10.44% (n=79) placebo @ 26wk4.5 mg
responder rate · % of participants
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
show 4 more results
43.97% (n=80) vs 10.44% (n=79) placebo @ 26wk2.4 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
35.79% (n=72) vs 10.44% (n=79) placebo @ 26wk1.2 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
24.06% (n=82) vs 10.44% (n=79) placebo @ 26wk0.6 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
15.28% (n=83) vs 10.44% (n=79) placebo @ 26wk0.3 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
Weight -11.8 vs -3.2 placebo kg @ 26wk4.5 mg
absolute change · kg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
show 4 more results
-10.1 vs -3.2 placebo kg @ 26wk2.4 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
-9 vs -3.2 placebo kg @ 26wk1.2 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
-7.1 vs -3.2 placebo kg @ 26wk0.6 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
-6.6 vs -3.2 placebo kg @ 26wk0.3 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
Waist Circumference Change -9.5 vs -3.4 placebo cm @ 26wk4.5 mg
absolute change · cm
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
show 4 more results
-8.1 vs -3.4 placebo cm @ 26wk2.4 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
-7.7 vs -3.4 placebo cm @ 26wk1.2 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
-6.2 vs -3.4 placebo cm @ 26wk0.6 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
-6.2 vs -3.4 placebo cm @ 26wk0.3 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
HbA1c -0.1% (n=95) vs -0.1% (n=94) placebo @ 26wk4.5 mg
absolute change · percentage points
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
show 4 more results
-0.1% (n=99) vs -0.1% (n=94) placebo @ 26wk2.4 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
-0.1% (n=95) vs -0.1% (n=94) placebo @ 26wk1.2 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
-0.1% (n=97) vs -0.1% (n=94) placebo @ 26wk0.6 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2
0% (n=93) vs -0.1% (n=94) placebo @ 26wk0.3 mg
NCT03856047 · Phase 2 · monotherapy · Obesity · phase 2

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: cagrilintide's landscape · MET-233i's landscape